Fluicell

Fluicell Rule of 40

The Rule of 40 of Fluicell (FLUI.ST) as of Nov 20, 2026 is 78.16 %. In the previous year, Rule of 40 was -896.49 % — a change of -108.72% (higher).

Rule of 40

78.16 %

YoY

-108.72%

Last updated:

Rule of 40 of Fluicell is 2025 78.16 % . Rule of 40 of Fluicell was 2024 -896.49 % . It decreases by -108.72% higher compared to the previous year.

The Fluicell Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-1,188.84 SEK
Jan 1, 2019
-647.99 SEK
Jan 1, 2020
-281.04 SEK
Jan 1, 2021
-877.64 SEK
Jan 1, 2022
-643.38 SEK
Jan 1, 2023
-802.57 SEK
Jan 1, 2024
-896.49 SEK
Jan 1, 2025
78.16 SEK
The Fluicell Rule of 40 history
YEARRule of 40YoY
78.16 %-108.72%
-896.49 %+11.70%
-802.57 %+24.74%
-643.38 %-26.69%
-877.64 %+212.28%
-281.04 %-56.63%
-647.99 %-45.49%
-1,188.84 %+55.02%
-766.92 %+649.31%
-102.35 %-116.06%
637.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Rule of 40 of Fluicell is 78.16 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Fluicell since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Fluicell

All Key Metrics — Fluicell